Prosecution Insights
Last updated: November 20, 2026
Application No. 17/593,909

A HIGH THROUGHPUT SEQUENCING METHOD AND KIT

Non-Final OA §103§DP
Filed
Sep 27, 2021
Priority
Mar 27, 2019 — EU PCT/EP2019/057777 +2 more
Examiner
SALMON, KATHERINE D
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Diagenode S A
OA Round
4 (Non-Final)
43%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allowance Rate
342 granted / 801 resolved
-17.3% vs TC avg
Strong +38% interview lift
Without
With
+38.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
71 currently pending
Career history
925
Total Applications
across all art units

Statute-Specific Performance

§101
19.4%
-20.6% vs TC avg
§103
28.2%
-11.8% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
35.2%
-4.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 801 resolved cases

Office Action

§103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The examiner prosecuting the application has changed. Please direct all future correspondences to Katherine Salmon. This action is in response to papers filed 4/16/2026. Claims 1-3, 5-6, and 8-10 are pending. Claims 4, 7, and 11-20 have been cancelled. The following rejections are Modified with response to arguments following. It is noted that claims 8-9 were previously not rejected under 35 USC 103. This action is Nonfinal. Withdrawn Rejections The 35 USC 112b rejection made in the previous office action is withdrawn based upon amendments to the claims. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Standard for Obviousness. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Attention is directed to In re Jung, 98 USPQ2d 1174, 1178 (Fed. Cir. 2011) wherein is stated: There has never been a requirement for an examiner to make an on-the-record claim construction of every term in every rejected claim and to explain every possible difference between the prior art and the claimed invention in order to make out a prima facie rejection. This court declines to create such a burdensome and unnecessary requirement. “[Section 132] does not mandate that in order to establish prima facie anticipation, the PTO must explicitly preempt every possible response to a section 102 rejection. Section 132 merely ensures that an applicant at least be informed of the broad statutory basis for the rejection of his claims, so that he may determine what the issues are on which he can or should produce evidence.” Chester, 906 F.2d at 1578 (internal citation omitted). As discussed above, all that is required of the office to meet its prima facie burden of production is to set forth the statutory basis of the rejection and the reference or references relied upon in a sufficiently articulate and informative manner as to meet the notice requirement of § 132. As the statute itself instructs, the examiner must “notify the applicant,” “stating the reasons for such rejection,” “together with such information and references as may be useful in judging the propriety of continuing prosecution of his application.” 35 U.S.C. § 132. Attention is directed to the decision in KSR International Co. v. Teleflex Inc., 82 USPQ2d 1385 (U.S. 2007): When there is a design need or market pressure to solve a problem and there are a finite number of identified, predictable solutions, a person of ordinary skill in the art has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense. It is further noted that prior art is not limited to the four corners of the documentary prior art being applied. Prior art includes both the specialized understanding of one of ordinary skill in the art, and the common understanding of the layman. It includes “background knowledge possessed by a person having ordinary skill in the art. . . [A] court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR at 1396. Suggestion, teaching or motivation does not have to be explicit and “may be found in any number of sources, including common knowledge, the prior art as a whole or the nature of the problem itself’” Pfizer, Inc. v. Apotex, Inc. 480 F.3d 1348, 82 USPQ2d 1321 (Fed. Cir. 2007) citing Dystar Textilfarben GMBH v. C. H. Patrick Co., 464 F.3d 1356 (Fed. Cir. 2006). Holding and Rationale Claim(s) 1-3, 5-6, and 10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Macosko et al. (2015) (Macosko et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets, Cell, 2015 May 21;161(5):1202-1214. doi: 10.1016/j.cell.2015 .05.002) in view of Suresh et al. (2017) (Suresh et al., Next-generation sequencing for endocrine cancers: Recent advances and challenges, Tumour Biol., 2017 May;39(5):1010428317698376. doi: 10.1177/1010428317698376). Notes: The teachings of Macosko et al. (2015) have been documented in Non-Final of 17/039,126 mailed on 12/07/2022, pages 5-12. Application 17/039,126 became US Patent number 11,788,137. Fig. 1 of Macosko et al. (2015) is copied below. PNG media_image1.png 334 858 media_image1.png Greyscale Figure 1. Molecular Barcoding of Cellular Transcriptomes in Droplets (A) Drop-Seq barcoding schematic. A complex tissue is dissociated into individual cells, which are then encapsulated in droplets together with microparticles (gray circles) that deliver barcoded primers. Each cell is lysed within a droplet; its mRNAs bind to the primers on its companion microparticle. The mRNAs are reverse-transcribed into cDNAs, generating a set of beads called ‘‘single-cell transcriptomes attached to microparticles’’ (STAMPs). The barcoded STAMPs can then be amplified in pools for high-throughput mRNA-seq to analyze any desired number of individual cells. (B) Sequence of primers on the microparticle. The primers on all beads contain a common sequence (‘‘PCR handle’’) to enable PCR amplification after STAMP formation. Each microparticle contains more than 108 individual primers that share the same ‘‘cell barcode’’ (C) but have different unique molecular identifiers (UMIs), enabling mRNA transcripts to be digitally counted (D). A 30-bp oligo dT sequence is present at the end of all primer sequences for capture of mRNAs. (C) Split-and-pool synthesis of the cell barcode. To generate the cell barcode, the pool of microparticles is repeatedly split into four equally sized oligonucleotide synthesis reactions, to which one of the four DNA bases is added, and then pooled together after each cycle, in a total of 12 split-pool cycles. The barcode synthesized on any individual bead reflects that bead’s unique path through the series of synthesis reactions. The result is a pool of microparticles, each possessing one of 412 (16,777,216) possible sequences on its entire complement of primers (see also Figure S1). (D) Synthesis of a unique molecular identifier (UMI). Following the completion of the ‘‘split-and-pool’’ synthesis cycles, all microparticles are together subjected to eight rounds of degenerate synthesis with all four DNA bases available during each cycle, such that each individual primer receives one of 48 (65,536) possible sequences (UMIs). Macosko et al. (2015), does not explicitly teach the step of “obtaining concatemers that self-assemble into balls by performing a rolling circle replication of the circular DNA template”. Suresh et al. (2017), teach that “In the case of library preparation from microRNA (miRNA) and other small RNAs, gel-based size enrichment of the ligated fragments is essential to separate the miRNA library (120 bp adapters and ~30 bp miRNAs) from adapter dimer side products generated during ligation reactions (See left column, page 2. under section title “Short-read NGS”); and that “It involves a series of adapter ligations, circularization, a cleavage reaction, rolling circle amplification of the DNA, and the formation of complex DNA concatemers. These DNA nanoballs are then immobilized on a patterned flow cell for sequencing. (See right column, page 2. under section title “Short-read NGS”.) Suresh et al. (2017), page 2, right column, second paragraph, teach: The incorporation of dNTPs labeled with different fluorescent dyes allows each base to be individually identified. In addition, the dye acts as a terminator and is cleaved after base detection to identify the next base. The above teaching is deemed to fairly suggest limitations of claim 10. Suresh et al. (2017), page 2, right column, first paragraph, teach using Phi29 DNA polymerase. Such a showing is deemed to fairly suggest limitations of claim 6. Suresh et al. (2017), page 4, right column, first paragraph, teach using miRNA. Such a showing is deemed to fairly suggest limitations of claim 5. In view of the detailed teachings of the prior art, the sequencing methods set forth in claims 1-3, 5-6, and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Macosko et al. (2015) (Macosko et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets, Cell, 2015 May 21;161(5):1202-1214. doi: 10.1016/j.cell.2015 .05.002) in view of Suresh et al. (2017) (Suresh et al., Next-generation sequencing for endocrine cancers: Recent advances and challenges, Tumour Biol., 2017 May;39(5):1010428317698376. doi: 10.1177/1010428317698376). Response to Arguments The reply traverses the rejection a summary of the arguments have been provided below with response to arguments following. The reply asserts that the use of template switching in Macosko is to attach a PCR handle and that there is no suggestion that the circularization of the resulting DNA or the small RNA (p. 3). The reply asserts that Suresh suggests small RNAs but teaches using a series of adapter ligations, circularization and cleavage followed by RCA (p. 3). The reply asserts that the there are numerous sequencing methods and a myriad of combinations, however, that it is known in the prior art that circularization of small nucleic acids is challenging due to conformational restraints (p 3). The reply asserts that there is no discussion of how or why the specific elements would be combined however, it is not clear why the numerous steps of Suresh would be used in the method of Macosko nor the use of small RNA in place of mRNA (p. 3). These arguetmsn have been reviewed but have not been found persuasive. It is noted that the claims only require hybridizing a template nucleic acid to a untemplated C nutled to generate double stranded nucleic acid. As Macosko et al. taches the addition of a handle this would encompass the hybridization. It is suggested that the claim be amended to more fully describe the switching if the circularization is required. Although there are numerous different combinations of method steps, this unto itself is not unpredictable as the steps skill are drawn to routine and known methods of hybridizing and immobilizing for the predictable outcome of sequencing. Although the use of smaller RNA would require optimization, it is noted that the sequencing of the RNA using the methodology of switching, ligation and RCA is well known in the prior art and exemplified above. As such the rejection based upon the breadth of the claims is maintained. Claim(s) 8-9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Macosko et al. (2015) (Macosko et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets, Cell, 2015 May 21;161(5):1202-1214. doi: 10.1016/j.cell.2015 .05.002) and Suresh et al. (2017) (Suresh et al., Next-generation sequencing for endocrine cancers: Recent advances and challenges, Tumour Biol., 2017 May;39(5):1010428317698376. doi: 10.1177/1010428317698376) as applied to claims 1-3, 5-6, and 10 and in view of Drmanac et al (US Patent Application Publication 2007/0099208 May 3, 2007). Macosko et al. and Suresh et al. teaches a method of sequencing based upon immobilizing the concatemers on a patterned array flow cell. However, Macosko et al. and Suresh et al. does not teach a method of a particular flow cell and binding. With regard to claim 8, Drmanac et al. teaches a patterned array flow cell that is silicon and photoresist (para 59-79). With regard to claim 9, Drmanac et al. teaches that attachment is done with aminiosilane functionalization (para 52). Therefore it would be prima facie obvious to one of ordinary skill at the time of the effective filing date to modify the methods of Macosko et al and Suresh et al. to include a known flow cell that can be used for sequencing. As Drmanac et al. teaches flow cells that can be used in sequencing (para 4-10) it would be obvious to modify the method of Macosko et al. and Suresh et al. to use one of the finite types of flow cells with the expectation of sequencing. Maintained Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 3, 5, and 10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 1, 13, and 16 of U.S. Patent No. 11,788,137. Although the claims at issue are not identical, they are not patentably distinct from each other because claim 1 of U.S. Patent No. 11,788,137 is drawn to a method of sequencing which requires the production of a cDNA, making it double stranded, the use of “template switching nucleic acid sequence” and the sequencing of same. Claims 1 and 2 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 11, 12, and 13 of copending Application No. 18/459,195 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of 18/459,195, like that of the instant application, are drawn to a method of sequencing of a cDNA molecule which has undergone amplification. Claim 13 of 18/459,195 is much like claim 2 of the instant application This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments The reply asserts that the applications were filed later and therefore the terminal disclaimer is not required. This has been allowed but it is noted that as the application has not been allowed the rejection is maintained. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE D SALMON whose telephone number is (571)272-3316. The examiner can normally be reached 9-530. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Cheng (Winston) Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE D SALMON/ Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Show 5 earlier events
Sep 22, 2025
Final Rejection mailed — §103, §DP
Oct 03, 2025
Response after Non-Final Action
Nov 20, 2025
Request for Continued Examination
Nov 21, 2025
Response after Non-Final Action
Nov 26, 2025
Non-Final Rejection (signed) — §103, §DP
Jan 20, 2026
Non-Final Rejection mailed — §103, §DP
Apr 16, 2026
Response Filed
Sep 23, 2026
Non-Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767985
METHODS OF DIAGNOSING A DISEASE STATE
5y 4m to grant Granted Oct 20, 2026
Patent 12760366
METHODS FOR DETERMINING RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR THERAPY IN THE TREATMENT OF PSORIASIS
4y 6m to grant Granted Oct 13, 2026
Patent 12748103
METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS
3y 9m to grant Granted Sep 29, 2026
Patent 12729405
METHOD AND KIT FOR DETERMINING BENEFIT OF CHEMOTHERAPY
4y 6m to grant Granted Sep 08, 2026
Patent 12709776
NOVEL MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION IN PANCREATIC CANCER
4y 12m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
43%
Grant Probability
81%
With Interview (+38.2%)
4y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 801 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month